FDA Panel Votes to Recommend BPC-157 for Pharmacy Compounding
A federal advisory panel voted on July 23, 2026 to recommend adding BPC-157 to the FDA’s compounding list. The vote was 8 to 6, with one member abstaining. It is the strongest regulatory signal yet for the most widely offered peptide in American clinics.
The recommendation surprised many observers. FDA staff had proposed keeping BPC-157 and six other peptides off the list entirely.
HealingMaps may earn a commission when readers sign up through Live Vital. This does not affect our editorial coverage. Compounded peptides are not FDA-approved finished products; the July 23 vote is an advisory recommendation, not final FDA authorization. Eligibility is determined by Live Vital’s licensed providers.
Key Takeaways
| Question | What We Know |
|---|---|
| What passed? | The committee recommended adding BPC-157 to the 503A bulks list |
| How close was it? | 8 votes in favor, 6 against, 1 abstention |
| Is compounding legal now? | No. The recommendation is advisory. FDA rulemaking comes next |
| What about the other peptides? | TB-500, KPV and MOTS-c results were not yet published at press time. Three more get votes July 24 |
| Who is affected? | BPC-157 appears on 55.3% of the 846 verified clinic menus we track |
An 8 to 6 Vote Against the Agency’s Own Review
The Pharmacy Compounding Advisory Committee met July 23 and 24 to review seven peptides. According to Reuters reporting on the vote, the panel recommended placing BPC-157 on the list that governs pharmacy compounding.
That outcome broke with the agency’s own staff review. FDA briefing documents released before the meeting proposed the same conclusion for all seven peptides: do not add them. The committee weighed proposed uses that included wound healing and ulcerative colitis. None of the seven compounds has completed the large trials required for full drug approval.
The meeting drew unusual attention for an obscure committee. The public docket collected roughly 1,860 comments. The FDA also expanded the panel with eight new members in the weeks before the vote.
Can Clinics Start Compounding BPC-157 Tomorrow?
No. This vote does not change what a pharmacy can compound tomorrow. A committee recommendation is advisory and not binding. It hands the FDA guidance, not a rule.
Whether a pharmacy may compound BPC-157 right now turns on a separate FDA policy. That policy governs enforcement while the agency reviews these peptides. Thursday’s vote did not touch it. So the rules on the ground read the same today as they did last week.
What Happens Next
A favorable vote starts a long process, not a quick switch. The path from here runs through federal rulemaking. Each step below takes months.
| Step | What Happens |
|---|---|
| 1. FDA review | The agency decides whether to act on the committee’s recommendation |
| 2. Proposed rule | If it proceeds, the FDA publishes a proposed rule in the Federal Register |
| 3. Public comment | A comment period opens, usually 60 to 90 days |
| 4. Final rule | The FDA weighs the comments and issues its final decision |
Legal analysts put the typical timeline at 12 to 18 months from a positive vote to a final rule, as this review of the FDA’s peptide compounding actions explains. The agency can also decline to follow the committee. The proposed rule can change during the comment period.
The direction still matters. A place on the 503A list would give licensed compounding pharmacies a clear legal basis to prepare BPC-157 for individual patients with valid prescriptions. Details of the meeting agenda and briefing materials are posted on the FDA advisory committee calendar.
How Much of the Industry Rides on This Compound
No compound touches more clinic menus than this one. Our national menu analysis found BPC-157 ahead of every other peptide in America, including semaglutide.
The exposure runs deeper than one compound. More than half the industry offers at least one peptide from this week’s docket. The full breakdown appears in our report on the state of peptide medicine in America.
What Clinic Operators Should Do Now
We published a plan for this exact outcome. Our guide to what a yes vote on BPC-157 means for your clinic covers the next steps in detail. Three points deserve attention first.
Watch your marketing language. A recommendation is not an approval, and “FDA approved” claims remain off limits. Talk to your pharmacy about sourcing plans under a potential rule change. Prepare for patient questions, because coverage of this vote will reach them fast.
The Votes Still to Come
Day one of the meeting also included votes on TB-500, KPV and MOTS-c. Those results had not been published when this article went live. The committee returns on July 24 to consider DSIP, Semax and Epitalon.
We will update this coverage as results post. Our earlier preview of the seven peptides under FDA review explains what each compound does and why it was nominated.
